OXADIAZOLAMINE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Russian patent published in 2019 - IPC C07D413/04 C07D413/14 C07D271/06 A61K31/4245 A61K31/506 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: present invention relates to a compound of an oxadiazolamine derivative of formula I, where R₁ is -CF₂H or -CF₃; L₁ and L₂ are absent; Z₁–Z₄, each independently represents N or CR^Z {where three or more Z₁–Z₄ can not simultaneously represent N}, where R^Z is -H; R₂ is -H; Y₁ is -CH₂-, -NR^c-, where R^C is -H, -C(=O)-O(C₁-C₄alkyl)phenyl; a and b, each independently, is integer of 0, 1, 2, 3 or 4 {where a and b, all can not be 0}; L₃ is -(C₁-C₂alkyl)-, -(C₁-C₂alkyl)-SO₂- or absent; ring B is -phenyl, -heteroaryl (selected from thiophene and pyridine), structure (a), where Z₅ and Z₆, each independently represents -O-; and R₄–R₆, each independently represents -H, -F, -Cl, -OH, -O(C₁-C₄alkyl), -(C₁-C₄alkyl), -CF₃, -OCF₃, heterocycloalkyl selected from piperidine and morpholine {where heterocycloalkyl can be unsubstituted or substituted with C₁-C₄alkyl}, structure (b), where Y₂ is -O-, Y₃–Y₅, each independently represents -CH- or -N-, c–f, each independently, is equal to integer 0, 1, 2 {where c and e, all can not be equal to 0, and d and f, all can not be equal to 0}. Invention also relates to a pharmaceutical composition for preventing or treating histone deacetylase 6 mediated disease containing a therapeutically effective amount of the compound of formula I, and at least one pharmaceutically acceptable carrier.

ring B,

structure (a),

structure (b).

EFFECT: oxadizolamine derivative according to the invention is intended for treating histone deacetylase 6 mediated disease.

10 cl, 3 tbl, 106 ex